NCT05826028 is a clinical trial in Secondary Progressive Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT05826028?

NCT05826028 is sponsored by Novartis Pharmaceuticals.

What condition does NCT05826028 study?

NCT05826028 studies Secondary Progressive Multiple Sclerosis.

Is NCT05826028 still recruiting?

NCT05826028 is currently completed. Last updated 24 April 2023.

Last reviewed 2023-04-24 · How we verify

NCT05826028

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo

Completed Last updated 24 April 2023

What this trial tests

trial in Secondary Progressive Multiple Sclerosis in 368 participants. Completed in 20 April 2022.

Timeline

9 July 2020

Primary endpoint
20 April 2022

20 April 2022

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Status	Completed
Study type	OBSERVATIONAL
Enrollment	368
Start date	9 July 2020
Primary completion	20 April 2022
Estimated completion	20 April 2022
Sites	2 locations across Australia

Conditions studied

Secondary Progressive Multiple Sclerosis — all drugs for Secondary Progressive Multiple Sclerosis →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Secondary Progressive Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was a retrospective, non-interventional, longitudinal, descriptive study. This study did not have a key underlying hypothesis, rather it was designed to explore the onboarding and adherence of SPMS patients in Australia to Mayzent (siponimod) treatment. Initiating siponimod involves pre-screen tests, including a CYP2C9 genotype test to determine siponimod maintenance dosing, and patients underwent a 6-day titration prior to maintenance. The MSGo platform was developed to support onboarding. It is an integrated digital platform that functions as a patient support service.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Secondary Progressive Multiple Sclerosis

Currently open trials in the same condition.

NCT06372145 — A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. · Phase 3 · active not recruiting
NCT05327322 — Functional Outcomes From Diets in Multiple Sclerosis · NA · active not recruiting
NCT04688788 — Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis · Phase 3 · active not recruiting
NCT03783416 — SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis · Phase 1 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05826028 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 24 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05826028.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing